IQGAP scaffolding proteins regulate many essential cellular processes including growth factor receptor signaling, cytoskeletal rearrangement, adhesion and proliferation, and are highly expressed in many cancers. Using genetically engineered human skin tissue in vivo, we demonstrate that diminished, sub-physiologic expression of IQGAP1 or IQGAP3 is sufficient to maintain normal epidermal homeostasis, while significantly higher levels are required to support tumorigenesis. To target this tumor-specific IQGAP requirement in vivo, we engineered epidermal keratinocytes to express individual IQGAP protein domains designed to compete with endogenous IQGAPs for effector protein binding. Expression of the IQGAP1-IQM decoy domain in epidermal tissue in vivo inhibits oncogenic Ras-driven MAPK signaling and antagonizes tumorigenesis, without disrupting normal epidermal proliferation or differentiation. These findings define essential non-redundant roles for IQGAP1 and IQGAP3 in epidermis, and demonstrate the potential of IQGAP antagonism for cancer therapy.
Introduction
The progression of invasive neoplasia frequently involves dysregulation of cellular signals that are integral to normal processes. Therapeutics against common oncogenic drivers often directly interfere with central components of core signaling pathways, and their clinical utility is limited by toxicity to normal cells. In this regard, blocking cell-signaling scaffolding molecules, in addition to oncogenic drivers, may be a promising strategy. As modulators of EGFR and MAPK signaling, IQGAPs may be useful therapeutic targets.
IQ motif-containing GTPase activating proteins (IQGAPs) are a family of ubiquitouslyexpressed scaffolding proteins that coordinate signaling pathways by facilitating physical interactions between effector proteins to enhance signal transduction . The IQGAP family is comprised of three isoforms (IQGAP1, IQGAP2, and IQGAP3) which each contain multiple protein recognition domains: the F-actin-binding calponin homology domain (CHD); a polyproline-binding region (WW) that binds Erk 1/2; an IQ motif (IQM) that binds to MEK1/2, Raf, EGFR and Calmodulin; the Ras GAP related domain (RGD) which binds to Rac1 and Cdc42; and the C-terminal (RGCT) domain which interacts with E-cadherin, β-catenin, APC, and Clip-170 ( Figure 1A ) (Fukata et al., 2002; Johnson et al., 2009; White et al., 2009) . Through these interactions, IQGAPs regulate growth factor receptor signaling, MAPK flux, cell-cell adhesion, cell cycle regulation and cytoskeletal rearrangements (Briggs and Sacks, 2003; White et al., 2012) -all critical cellular processes that are tightly coordinated both spatially and temporally for proper epidermal growth and differentiation.
Despite the role that IQGAP scaffolds play in supporting these key cell functions, IQGAP1 null mice develop normally (Li et al., 2000) . The lack of an overt phenotype suggests the possibility of functional rescue by another IQGAP isoform(s) in mice. In this regard, IQGAP3 seems the most likely candidate, as it shares 60% homology to IQGAP1 and has a relatively broad expression pattern (White et al., 2012) . While IQGAP3 null murine tissue has not been generated, RNAi studies in the mouse epithelial cell line Eph4 demonstrate that, like IQGAP1, IQGAP3 also facilitates signaling through MAPK (Nojima et al., 2008) . IQGAP2 expression is much more limited and expressed predominantly in the liver, gastrointestinal tract, and platelets (Nojima et al., 2008) . IQGAP2 is not expressed in skin. The effects of acute IQGAP loss in adult murine or human tissue have not been studied, but are potentially important to examine as phenotypes resulting from protein loss in developed tissues can vary significantly from those observed with loss during embryogenesis. Further, mouse and human tissues may differ with regard to their specific IQGAP requirements.
IQGAP1 is upregulated in many human cancers including lung, colon, liver, breast, glioblastoma, and melanoma (Clark et al., 2000) , and regulates core cellular processes critical for malignant progression including proliferation, adhesion, and migration. Since progression to invasive neoplasia frequently involves dysregulation of normal cellular processes rather than activation of pathways completely lacking in the normal tissue, targeting central components of dysregulated pathways often results in high toxicity. As modulators rather than required core elements of key oncogenic signaling pathways, IQGAP1 or IQGAP3 may be uniquely poised therapeutic targets.
In this study, we define the roles of IQGAP1 and IQGAP3 in both human epidermal homeostasis and invasive epithelial cancer, by using genetically-defined human skin tissues maintained in their native, orthotopic location in vivo (Ridky et al., 2010) . Tissues were generated using primary keratinocytes expressing shRNAs against IQGAP1 or IQGAP3. We show that the effects of IQGAP loss vary with the extent of the knockdown, as partial knockdown (50-85%) of either IQGAP1 or IQGAP3 was well tolerated in normal tissues, while more complete knockdown (85-95%) resulted in marked proliferation arrest and tissue failure in vivo. We also engineered human tissue grafts to express tumor-associated oncogenes sufficient to drive squamous cell carcinoma (SCC), and demonstrate a tumorspecific requirement for increased IQGAP1 and IQGAP3 in this cancer context. Finally, we developed an interfering decoy peptide based on the IQGAP-IQM domain that selectively inhibits oncogenic Ras activity in tissue. These findings establish the requirements of IQGAP1 and IQGAP3 in epidermal homeostasis and cutaneous tumor progression, and establish the potential therapeutic utility of targeting IQGAPs in human cancer.
RESULTS

IQGAP1 and IQGAP3 are expressed in normal human epidermis and in epidermal squamous cell carcinoma
Both normal human skin and spontaneous human SCC tumor tissues display robust IQGAP1 and IQGAP3 expression ( Figure 1B ). IQGAP1 is located throughout all layers of the epidermal compartment, whereas IQGAP3 expression is concentrated within the proliferative basal cells, and relatively absent in the post-mitotic suprabasal layers ( Figure  1B , Figure S1 ). Within keratinocytes, IQGAP1 and IQGAP3 are localized throughout the cytoplasm, and are also concentrated at the plasma membrane. This expression and cellular distribution reflects the diversity of scaffolding activities and interacting effector proteins, and is consistent with IQGAP expression patterns in other tissues (Berglund et al., 2008; Nabeshima et al., 2002) . We were unable to detect IQGAP2 protein in skin tissue or cultured primary keratinocytes (data not shown), consistent with its previously established limited tissue distribution (White et al., 2009; White et al., 2012) .
IQGAP1 and IQGAP3 are both required for human epidermal keratinocyte proliferation
To determine the degree to which IQGAP1 and IQGAP3 are required for normal epidermal function, we generated stable populations of primary, early passage human IQGAP1 or IQGAP3 knockdown (IQGAP1i or IQGAP3i) keratinocytes utilizing lentiviral transduction to drive constitutive shRNA expression. Several lentivectors were used for each IQGAP to achieve varying levels of knockdown ( Figure 2A , Figure S2 ). The pGIPZ, miR-30 based, IQGAP interference resulted in 50% IQGAP1 protein knockdown, and a 85% IQGAP3 protein knockdown, referred to here as IQ1i Mod and IQ3i Mod respectively. With these levels of knockdown, loss of either IQGAP1 or IQGAP3 does not impact the expression level of the other isoform. More complete knockdown was obtained with the pLKO U6-driven lentivectors, which resulted in IQGAP1 and IQGAP3 RNA knockdown of 90% and 96%, respectively, referred to as IQ1i Lo and IQ3i Lo (Figure 2A, B) . In contrast to the moderate knockdowns, severe depletion of IQGAP1 also resulted in concurrent depletion of IQGAP3 protein. This is likely a consequence of the proliferative arrest in the IQ1i Lo cells (discussed further below). IQGAP1 protein and transcript levels remained relatively normal in IQ3i Lo cells ( Figure 2A , B and Figure S3 ).
While the IQ1i Mod and IQ3i Mod keratinocytes are morphologically indistinguishable from controls, and proliferate normally in culture, the growth of IQ1i Lo and IQ3i Lo keratinocytes was markedly inhibited ( Figure 2C , Figure S2 ). This demonstrates that while normal cellular proliferation can be maintained with significantly diminished IQGAP1 or IQGAP3, they are not completely dispensable, nor functionally redundant in this context. The proliferative defect in primary human keratinocytes highlights a phenotypic difference between the human and mouse genetic systems. The observation that IQGAP3 expression is lost in the IQ1i Lo cells is likely a consequence of the associated growth arrest, rather than a direct consequence of IQGAP1 loss itself, as IQGAP3 expression has been previously shown to be limited to proliferating cells (Nojima et al., 2008) . To confirm that the decrease in IQGAP3 is not specifically dependent on IQGAP1 loss, primary keratinocytes were mitotically arrested with mitomycin-c. While IQGAP1 levels remained robust in mitomycin-c treated, non-proliferating cells, IQGAP3 levels dropped precipitously ( Figure S1 ).
IQGAP1 and IQGAP3 are both required for EGFR activation and MAPK signaling
IQGAP scaffolds orchestrate a signaling axis from EGFR through the MAPK cascade, by physically binding to EGFR, BRaf, MEK1/2, and ERK1/2, and modulating their activities McNulty et al., 2011) . In the absence of this scaffold, IQ1i Lo and IQ3i Lo cells displayed no detectable active phospho-EFGR, and also expressed less total EGFR protein ( Figure 2D ). This diminished EGFR activation is not the result of decreased EGFR transcription ( Figure S4 ). It is also unlikey to result from decreased EGFR ligand expression, as the major keratinocyte EGFR ligands including amphiregulin (Stoll et al.) are only modestly affected by IQGAP antagonism ( Figure S4 ), and exogenous EGF is routinely included in the cell culture media. In agreement with decreased EGFR activity, IQGAPi was associated with marked reduction in phospho-ERK. IQ1i Lo and IQ3i Lo keratinocytes also failed to maintain cyclin-D levels, consistent with loss of MAPK signaling (Diehl et al., 1997) . As MAPK signaling flux downstream of EGFR is the primary mitogenic stimulus for epidermal keratinocytes, loss of this signaling is likely directly responsible for the proliferative arrest in IQ1i Lo and IQ3i Lo cells. Consistent with this, p16 protein was relatively unchanged ( Figure 2D ), indicating that the proliferative arrest likely results from loss of mitogenic signaling rather than cellular senescence. Further, the lack of proliferation was not a consequence of a prematurely engaged differentiation or apoptotic program ( Figure S5 ). In contrast to IQ1i Lo and IQ3i Lo cells, IQ1i Mod and IQ3i Mod cells proliferated normally in culture without significant changes in MAPK signaling ( Figure 2D ).
Invasive squamous cell carcinoma requires higher levels of IQGAP1 and IQGAP3 than does normal epidermis
The profound proliferative defect in the IQGAPi cells was somewhat unexpected given the lack of overt phenotype in the IQGAP1 null mouse (Li et al., 2000) . To explore the possibility that this difference was the result of in vitro 2-dimensional culture versus 3-dimensional tissue in vivo, we next used our human IQGAPi keratinocytes to regenerate 3-D organotypic skin tissues employing native human dermis with intact basement membrane (Ridky et al., 2010) . These organotypic platforms support keratinocyte stratification and differentiation in vitro that recapitulate the structure and function of human skin. Engineered tissues can subsequently be grafted into the orthotopic location on the backs of immunodeficient mice for long-term in vivo study. Given that one of the hallmark features of epidermal tissues is a relatively high rate of basal cell proliferation and continual epidermal renewal, it was not surprising that attempts to establish 3-D in vitro organotypic, or in vivo xenograft skin using the nonproliferative IQ1i Lo and IQ3i Lo keratinocytes were unsuccessful. However, tissues generated using IQ1i Mod and IQ3i Mod keratinocytes, form functional epidermis both in vitro and in vivo. These tissues display normal basal proliferation and execute a normal stratification and differentiation program ( Figure 3A) . Thus, the phenotype of the 3-D organotypic experiments parallels that seen in 2-D cultures, and highlights the human requirement for basal maintenance of both IQGAP1 and IQGAP3 for normal epidermal homeostasis.
After establishing the IQGAP requirements in normal epidermis, we then explored the role of IQGAP in epidermal tumorigenesis using a genetically defined, in vivo SCC model (Lazarov et al., 2002) . For this approach, stable populations of non-silencing or IQGAPi Mod keratinocytes were engineered to express constitutively active oncogenic Ras and CDK4. These two oncogenic drivers alter centrally acting pathways frequently deregulated in spontaneous human SCC (Lazarov et al., 2002; Ridky et al., 2010) . When used to generate surface skin grafts in vivo, oncodriver-expressing keratinocytes harboring non-silencing shRNA control formed hyperproliferative tumors that degraded the basement membrane and invaded deeply into supporting stroma -recapitulating hallmark features of spontaneous human SCC. In contrast, IQ1i Mod and IQ3i Mod grafts displayed marked attenuation of the tumor phenotype ( Figure 3B ). IQ1i Mod and IQ3i Mod tissues were only mildly hyperplastic, with only a few focal areas of early invasion. The baseline MAPK activation that persists in IQ1i Mod and IQ3i Mod keratinocytes (and is sufficient to support normal epidermis) is insufficient to support the full oncogenic effects of active Ras. These results indicate that significantly higher levels of IQGAP1 and IQGAP3 are necessary for the initiation and progression of invasive epidermal neoplasia than for the maintenance of normal human skin, and that IQGAP may therefore be a useful therapeutic target for human epidermal cancer. Consistent with this, IQGAP1 null mice are somewhat resistant to skin cancer induced by topical carcinogen (DMBA/TPA) application (Jameson et al., 2013) .
Oncogenic Ras effects are blocked with decoy peptides based on the IQGAP IQM domain
The markedly attenuated tumor invasion and proliferation observed with IQGAP knockdown suggests that IQGAP may be a useful therapeutic target for cancer. To begin exploring this possibility we sought to antagonize IQGAP activity by targeting its interactions with protein effectors in a domain-specific fashion. To accomplish this, we constructed five lentiviruses, each designed to drive expression of a single IQGAP structural domain. We hypothesized that expression of these isolated IQGAP peptide domain "decoys" in keratinocytes may compete with endogenous IQGAP for effector binding and interfere with signaling.
To quantitatively determine the degree of fitness advantage or disadvantage conferred by each of the domains in the context of intact epidermal tissue, we utilized a multiplexed competition assay ( Figure 4A ). In this approach, six different populations of keratinocytes, each engineered to express a single IQGAP domain (or luciferase control), along with a uniquely bar-coded fluorescent protein, were pooled in equal ratios and used to generate epidermis in vivo. After 4 weeks of in vivo selection, tissues were harvested and analyzed. Quantitative polymerase chain reaction (qPCR) was used to determine the relative representation of each cell population in the final resulting tissue, which was compared to that in the starting cell mixture. In the context of otherwise normal skin, none of the decoy peptides resulted in a fitness disadvantage, while four conferred a slight fitness advantage. However, in Ras-driven SCC tissue, cells expressing the isolated IQM domain displayed a significant fitness disadvantage (16-fold) ( Figure 4B ). Similar effects were observed in organotypic in vitro tissues with and without Ras oncogene challenge ( Figure 4C ). The expression of the IQM domain did not strongly alter endogenous expression of either IQGAP1 or IQGAP3, nor did it affect EGFR expression in primary keratinocytes ( Figure  S6 ). Similar inhibitory effects were not observed with any of the other 4 IQGAP domain peptides.
To more fully characterize the effects of IQGAP-IQM expression in human tissue, and to validate the effects seen in the multiplexed screen, we next expressed the IQM domain individually in engineered human skin xenografts. IQGAP-IQM expression in otherwise normal epidermis in vivo had no discernable effect on skin architecture or morphology ( Figure 5A ).
We then explored the effects of this single peptide in the SCC setting. IQGAP1-IQM keratinocytes were transformed with oncogenic Ras and CDK4, and used to establish both in vitro and in vivo organotypic skin tissues. In vitro, Ras expressing control tissues are hyperplastic, architecturally disordered, and degrade basement membrane with deep epithelial cell invasion into supporting stroma. The IQM decoy peptide significantly limits these oncogenic Ras effects, as tissues are markedly less hyperplastic, and lose invasive capacity ( Figure 5B ). Consistent with these in vitro results, IQM-expression also inhibits Ras oncogenic effects in xenografts in vivo. Resulting neoplastic IQM-tissues were markedly less hyperproliferative than controls ( Figure 5C ), displayed less architectural disorder, and contained only small focal areas of modest invasion. In contrast, control tumors were markedly larger and deeply invasive throughout the tumor ( Figure 5D ). Consistent with this significantly attenuated cancer phenotype, MAPK activity downstream of oncogenic Ras was also markedly reduced in the IQM expressing grafts, as evidenced by markedly decreased phospho-ERK ( Figure 5E ). The diminished size of IQM-expressing tumors is likely the direct result of the loss of MAPK flux. Correspondingly, IQMexpressing tumors display a significantly lower ki67+ proliferative index than control ( Figure S6 ). Diminished IQM-tumor progression is not the result of increased apoptosis or premature differentiation (as determined by TUNEL, keratin 10, and filaggrin) ( Figure S6 ).
Discussion
Proteins that are essential for neoplastic transformation, but relatively dispensable for normal tissue homeostasis, are ideal cancer targets. Here we demonstrate in vivo that IQGAP requirements are significantly higher in neoplastic epidermis, than in normal skin. Further, we demonstrate that IQGAP antagonism via IQM domain decoys may have potential as a therapeutic strategy for human cancer. As most human malignancies require increased RasRaf-MEK-ERK signaling, targeting the MAPK scaffolding function of IQGAPs may be effective as an orthogonal therapeutic approach to inhibiting the core Ras-MAPK elements directly.
Although IQGAP downregulation is well-tolerated, it seems that there is a critical minimum expression level of IQGAP1 and IQGAP3 that is required for maintaining primary keratinocyte proliferation. This demonstrates that endogenous IQGAP1 and IQGAP3 are not functionally redundant. There is no compensatory upregulation of one isoform with knockdown of the other. While our studies suggest that IQGAP1 and IQGAP3 function similarly in the maintainence of MAPK activity, they may differ with regard to their other tissue-context specific scaffolding roles, including regulation of cytoskeletal remodeling proteins. While IQGAP1 is expressed throughout the epidermal compartment and tumor, IQGAP3 expression is most prominent within the basal layer of normal skin and the advancing font of SCC tumors, where there may be a requirement for higher total levels of collective IQGAP activity.
The isolated IQM domain likely influences multiple IQGAP activities within keratinocytes that together results in less MAPK activity and attenuation of Ras-driven tumorigenesis. IQM was designed to interfere with oncogenic Ras signaling by competing with endogenous full-length IQGAP for binding to Raf and MEK, and thus limiting assembly of the coordinated signaling complex required for ERK phosphorylation. The IQM peptide may also inhibit Ras-induced paracrine signaling at the level of EGFR, a potent mitogenic signal for keratinocytes in culture or in tumor formation (Dlugosz et al., 1997 ) that signals through Ras-MAPK.
Currently available drugs targeting the MAPK pathway are small molecule, cell-permeable inhibitors. IQGAPs do not possess kinase activity and are not cell-surface proteins. Targeting them inside cells will therefore require a non-traditional approach. Engineering IQM domain with polyarginine or HIV TAT protein sequences would potentially allow exogenously supplied recombinant proteins to permeate tumor tissue. The feasibility of this strategy was recently demonstrated for an epitope tagged, polyarginine modified WW domain peptide, which when continually infused, slowed the growth of mouse pancreatic cancers, and tumor cell lines grown subcutaneously in immunodeficient mice (Jameson et al., 2013) . While we included the unmodified IQGAP WW domain in our initial screen, we did not detect any anti-tumor effects in our system. The reasons for this are unclear, but may relate to the addition of polyarginine, or epitope sequences in the other study, or the use of different in vivo tumor models.
In summary, our findings define non-redundant roles for IQGAP1 and IQGAP3 in normal human skin, and establish an elevated tumor-specific IQGAP requirement that can be targeted to inhibit Ras-driven human cancer growth in vivo.
Materials and Methods
Cell culture
All experiments were conducted using primary keratinocytes isolated from normal human skin by methods delineated previously (Lazarov et al., 2002; Ridky et al., 2010) . Keratinocytes were cultured in a 1:1 mix of Gibco Keratinocytes-SFM medium + Lglutamine + EGF + BPE and Gibco Cascade Biologics 154 medium with 1% penicillin/ streptomycin (Invitrogen, Carlsbad, CA). Transduced keratinocytes were fully selected before the commencement of each experiment. CDK4/Ras challenged keratinocytes were transformed prior to the initiation of three-dimensional cultures.
Lentiviral and Retroviral Production and Transduction
293T and 293-derivitive Phoenix cells (Swift et al., 2001) were cultured in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 5% FBS containing Antibiotic/ Antimycotic. Lentiviral and retroviral particle were generated according to Thermoscientific specifications and as described previously (Chudnovsky et al., 2005; Lazarov et al., 2002; Ridky et al., 2010) . Lentiviral shRNA constructs against IQGAP (OpenBiosystems, Lafayette, CO) were as follows: pGIPZ/sh-IQGAP1 (antisense: TGATATCCATGAGATTGAG), pGIPZ/sh-IQGAP3 (antisense: TGTCTTCTAGCACATCCTG), pLKO1/sh-IQGAP1 (antisense: AATGGAAATGTAGATTACTGG), pLKO1/sh-IQGAP3 (antisense: AACTTATCAGTCATGGCGAGG). Additional RNAi vectors targeting IQGAP1 at nucleotide position 864-884 (pLKO) and [4243] [4244] [4245] [4246] [4247] [4248] [4249] [4250] [4251] [4252] [4253] [4254] [4255] [4256] [4257] [4258] [4259] [4260] [4261] , and IQGAP3 at nucleotide 2848-2866 (pGIPZ) and 4120-4140 (pLKO) were used to validate findings, and displayed similar effects on keratinocyte growth ( Figure S2 ). Individual IQGAP1 protein binding domains and luciferase were cloned into the pRRL lentivector. For the production of viral particles, lentiviral constructs were co-transfected with viral packaging plasmids pCMVΔR8.91 and pUC-MDG into 293T cells using Fugene 6 Transfection Reagent (Promega, Fitchburg, WI).
For oncogenic transformation, 293-derivitive Phoenix cells stably transfected with HRas G12V or CDK4 R24C were used to generate retroviral particles. Keratinocytes that were previously transduced with IQGAP knockdowns, non-silencing controls, or individual IQGAP domain expressing constructs, were then transformed with these retroviral particles as described previously (Chudnovsky et al., 2005; Ridky et al., 2010) .
Proliferation assay
Cells were originally plated at 10,000 cells per cm 2 . At the indicated time points, cells were trypsinized and manually counted. Results are the means of three biological replicates (± s.d.).
Western Analysis
Cells were lysed in RIPA Buffer containing 1X protease inhibitors and 1X phosphatase inhibitors (Roche, Branchburg, NJ), and extracts analyzed by SDS-PAGE and western blotting. Primary antibodies used in this study include IQGAP1 (Millipore, Billerica, MA), IQGAP3 (Abcam, Cambridge, MA), Actin, pEGFR, EGFR, pERK, ERK, and cyclinD (Cell Signaling, Danvers, MA), and p16 (BD Pharmingen, San Diego, CA). After incubation with the appropriate secondary antibody, proteins were detected using either Luminata Crescendo Western HRP Substrate (Millipore, Billerica, MA) or ECL Western Blotting Analysis System (GE Healthcare, Lafayette, CO).
Organotypic culture and skin xenografts
Organotypic skin cultures were established using genetically engineered keratinocytes expressing IQGAP knockdowns, non-silencing controls, active Ras and CDK4 oncogenes, and individual IQGAP1 peptide domains. For each culture, between 8.0 × 10 5 and 1.0 × 10 6 keratinocytes were suspended in 80 μL KGM, seeded onto devitalized human dermis, and incubated at 37 °C at an air-liquid interface for three days prior to xenografting or for time indicated for in vitro OTC cultures according to previously established methods (Chudnovsky et al., 2005; Duperret et al., 2014; Ridky et al., 2010) .
For xenografting, OTCs were surgically grafted onto the back skin of 5-7 week old female ICR SCID mice (Taconic, Centre Hudson, NY). For each in vivo experiment, 2-3 animals were used per condition, and results were verified over three experimental replicates. Engineered tissues were generated by methods delineated previously (Lazarov et al., 2002; Ridky et al., 2010) .
For competition assays ( Figure 4A ), distinct populations of keratinocytes were engineered to express CHD, WW, IQM, GRD and RasGAP, or a luciferace control along with drug selectable markers and identifying barcodes, with or without oncogenic Ras/CDK4. These keratinocytes were then pooled in equal ratios and used to establish organotypic cultures, which were either maintained in vitro or xenografted on mice. To determine the relative fitness between the keratinocytes, transcript levels of the non-coding barcode for each of the domain decoys was analyzed against its relative abundance in the starting cell population by quantitative PCR. Three biological replicates were performed for each condition. All experiments involving animals were performed in accordance with a University of Pennsylvania IACUC-approved protocol.
Quantitative RT/PCR
RNA was extracted from cells and tissues according to the RNeasy Mini Kit protocol (Qiagen, Valencia, CA), and reverse transcribed to cDNA using the High Capacity RNA-to cDNA kit (Applied Biosystems, Grand Island, NY). Quantitative PCR of resulting cDNA was conducted using Power SYBR Green Master Mix (Applied Biosystems, Grand Island, NY) and gene-specific primers, in triplicate, on a ViiA 7 Real-Time PCR System (Life Technologies, Grand Island, NY). Relative expression was determined using the 2- [delta] [delta] Ct method.
Immunofluorescence microscopy
Whole mount cryosections were prepared for immunofluorescence microscopy as previously described (Ridky et al., 2010) . Briefly, slides were fixed in 4% paraformaldehyde or −20°C methanol, permeabilized as required and blocked with 5% goat serum/PBS, followed by incubation with primary antibodies, and secondary antibodies conjugated to fluorophores. Slides were mounted with Prolong Gold Antifade Reagent with DAPI (Life Technologies, Grand Island, NY). The primary antibodies used in this study were IQGAP1 and Collagen VII (Millipore, Billerica, MA), IQGAP3 (Abcam, Cambridge, MA), Desmogelin-3 (Invitrogen, Carlsbad, CA), and Keratin-5 (Covance, Conshohocken, PA).
Immunohistochemistry
Formalin fixed paraffin embedded (FFPE) tissue sections from xenografts were stained for pERK protein expression using peroxidase/DAB (diaminobenzidine)-complex method (EXPOSE biotin free detection kit, Abcam, Cambridge, MA). Tissue sections were deparaffinized and rehydrated. To retrieve the antigens, tissue sections were microwaved in 10mM Citrate buffer pH 6.0. To quench endogenous peroxidase, tissues were incubated in 3% H2O2. Afterward tissues were incubated with primary antibody to phospho-ERK (Cell Signaling) for three hours at room temperature. The secondary antibody, HRP conjugated goat anti-rabbit, was supplied with the kit and incubated 18 min at room temperature. Following multiple washes in TBS the antigen-antibody complex was visualized with 3.3% DAB-solution. The tissues were counterstained with hematoxylin and dehydrated prior to mounting coverslips.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. IQGAP1 and IQGAP3 are highly expressed in normal human epidermis and epidermal squamous cell carcinoma. (a) IQGAP1 and IQGAP3 are multidomain scaffolding proteins with highly homologous structural motifs and the ability to bind a range of cell signaling and cytostructrual molecules. (b) Cryosections of human normal and SCC tissue were prepared for immunofluorescence microscopy of IQGAP1 (green), IQGAP3 (red), and nuclei (blue), scale bar = 100 μm. IQGAP1 is expressed throughout the epidermal compartment of both normal and cancer tissue. IQGAP3 expression is concentrated within the proliferative basal layer. Keratin 5 (red) and Keratin 10 (green) differentiation markers are also shown in both normal and SCC tissue. 
